ICLUSIG PONATINIB 15 AND 45 MG

DESCRIPTION

Iclusig (ponatinib) is a kinase inhibitor. It is a cancer medicine that deals with the growth of some cancer cells and is used to treat chronic myeloid leukemia (CML),  or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL).To buy iclusig or to know its price contact 3S Corporation.

Manufacturer :-  ARIAD

ADDITIONAL INFORMATION

Strengths available :- 15 mg and 45 mg
 Form :- Tablets
Storage :- Store at controlled room temperature at 20°C to 25°C.
Is the medicine FDA approved :- US FDA Approved
Date of approval :- 14 December, 2012
Dosage :-  Start dosing with 45 mg once daily. Consider reducing the dose of Iclusig for patients with chronic phase (CP) CML and accelerated phase (AP) CML who have achieved a major cytogenetic response.

SIDE EFFECTS

Common side effects of Iclusig include: arterial thrombosis, venous thrombosis, cardiac failure, congestive heart failure, pleural effusion, bone marrow depression, conjunctival irritation, dizziness, dyspnea, eye pain, fluid retention, gastrointestinal hemorrhage, headache, hyperesthesia, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum lipase, paresthesia, peripheral edema, peripheral neuropathy, and xerophthalmia. 
 
Other side effects include: acute myocardial infarction, pancreatitis, severe bone marrow depression, supraventricular tachycardia, blurred vision, coronary artery disease, hemorrhage, hyperuricemia, and tachyarrhythmia.

PACK SIZE

 Pack of 30 tablets and 60 tablets.

Reviews

There are no reviews yet.

Be the first to review “ICLUSIG PONATINIB 15 AND 45 MG”

Your email address will not be published. Required fields are marked *